Hochschulschrift
Group Sequential and Adaptive Designs for Three-Arm 'Gold Standard' Non-Inferiority Trials
- Weitere Titel
-
Gruppensequentielle und Adaptive Verfahren für Drei-Armige 'Gold-Standard' Nicht-Unterlegenheitsstudien
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Bremen, Universität Bremen, Diss., 2014
- Ereignis
-
Veröffentlichung
- (wo)
-
Bremen
- (wer)
-
Staats- und Universitätsbibliothek Bremen
- (wann)
-
2014
- Urheber
- Beteiligte Personen und Organisationen
-
Brannath, Werner
Timm, Jürgen
- URN
-
urn:nbn:de:gbv:46-00103851-12
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Schlömer, Patrick
- Brannath, Werner
- Timm, Jürgen
- Staats- und Universitätsbibliothek Bremen
Entstanden
- 2014
Ähnliche Objekte (12)
Group sequential and adaptive designs for three-arm "Gold-Standard" non-inferiority trials
Planning and analysis of two- and three-arm non-inferiority trials
Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints
Understanding the null hypothesis (H0) in non-inferiority trials
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Evidence-based sizing of non-inferiority trials using decision models
Phase IV non-inferiority trials and additional claims of benefit
Is there a danger of “biocreep” with non-inferiority trials?
Maximum likelihood theory for retention of effect non-inferiority trials
Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology
The use of randomisation-based efficacy estimators in non-inferiority trials
Response to: Understanding the null hypothesis (H0) in non-inferiority trials
Group sequential and adaptive designs for three-arm "Gold-Standard" non-inferiority trials
Planning and analysis of two- and three-arm non-inferiority trials
Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints
Understanding the null hypothesis (H0) in non-inferiority trials
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Evidence-based sizing of non-inferiority trials using decision models
Phase IV non-inferiority trials and additional claims of benefit
Is there a danger of “biocreep” with non-inferiority trials?
Maximum likelihood theory for retention of effect non-inferiority trials
Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology
The use of randomisation-based efficacy estimators in non-inferiority trials
Response to: Understanding the null hypothesis (H0) in non-inferiority trials
Group sequential and adaptive designs for three-arm "Gold-Standard" non-inferiority trials
Planning and analysis of two- and three-arm non-inferiority trials
Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints
Understanding the null hypothesis (H0) in non-inferiority trials
Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation
Evidence-based sizing of non-inferiority trials using decision models
Phase IV non-inferiority trials and additional claims of benefit
Is there a danger of “biocreep” with non-inferiority trials?
Maximum likelihood theory for retention of effect non-inferiority trials
Non-efficacy benefits and non-inferiority margins: a scoping review of contemporary high-impact non-inferiority trials in clinical cardiology
The use of randomisation-based efficacy estimators in non-inferiority trials